Eisai continues collaboration on next generation anti-malaria drugs

Japan’s Eisai (TYO: 4523) and contract research organization (CRO) Charles River Laboratories International (NYSE: CRL) have agree to extend their two-year collaboration in integrated drug discovery for another year.

The continued collaboration strengthens the ongoing partnership between the two companies, focusing on the discovery of novel treatments for tropical and neurological diseases at Eisai's state-of-the-art European Knowledge Center.

"We are excited to have the opportunity to continue our good work with the Charles River scientists at our European Knowledge Center, in order to address the unmet medical needs of patients and their families" said Gary Hendler, chairman and chief executive Eisai EMEA. "As a collaborative partner, Charles River has a proven track record of success in drug discovery and innovative chemistry capabilities. This partnership supports Eisai's commitment to investigating and developing innovative treatments, in line with our human health care mission," he added.